Abstract
This study is an evaluation of prescription opioid use on the island of La Gomera, a mainly rural area, during the period 2016–2019 at various levels. Data were extracted from the wholesalers who supply the community pharmacies at the population level. Prescription opioid use was measured as defined daily doses per 1,000 inhabitants/day (DID) and by the number of units sold per 1,000 inhabitants and year (units sold). This provided an island total of La Gomera’s overall prescription of opioids and its rate of change, as well as differences in prescribing at the municipal and health area level. Tramadol with acetaminophen and tramadol in monotherapy were the most consumed by “units sold” parameter, which accounted for 69.48% and 18.59% of the total. The situation was similar for DID, although with lower percentages, but a significant increase was observed in the use of fentanyl and buprenorphine, around 15% in each case. The balance between the uses of weak or strong opioids was different in La Gomera compared to that of Spain as a whole. In Spain, almost 70% of the prescriptions were for weak opioids compared to 58.67% in La Gomera. Fentanyl was the most used strong opioid (16.10%) followed by tapentadol and buprenorphine, around 5% each, whereas in La Gomera, buprenorphine was the most consumed (15.75%) followed by fentanyl (14.87%) and tapentadol (5.82%). These differences in prescription opioid use are most likely explained by prescriber characteristics, whereas the population age, socioeconomic status, or living in rural/urban area are not decisive determinants.
Highlights
A drug utilization study (DUS) includes the analysis of the commercialization, distribution, prescription, and use of medicines in the society, with special attention paid to the results of medical, social, and economic consequences (WHO 2020)
The study of prescription opioid use at the inpatient level was conducted using the Anatomical Therapeutic Chemical classification (ATC)/defined daily dose (DDD) methodology, which is internationally accepted for measuring drug utilization within and across populations
The results show that there is no significant correlation between the prescription opioid use rate, expressed as DID, and the population-aging rate at the municipal level
Summary
A drug utilization study (DUS) includes the analysis of the commercialization, distribution, prescription, and use of medicines in the society, with special attention paid to the results of medical, social, and economic consequences (WHO 2020). The DUS here used the prescription data from a nationwide drug data bank as the main source of information (Hamunen et al 2008; Jarlbaek 2019). Each country’s prescription database can be accessed on the Internet to obtain more detailed information on the annual number of prescribed opioids (Jarlbaek 2019). The treatment of chronic pain comprises both pharmacological and non-pharmacological strategies (Merskey and Bogduk 1994; Collins et al 1997; Dale et al 2005). Among the former are non-opioid pain relievers, opioids, and adjuvants (used to prevent or treat side effects of pain relievers or to enhance the pain relief itself)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.